A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer.
Chih Yang Huang,Da Tong Ju,Chih Fen Chang,P. Muralidhar Reddy,Bharath Kumar Velmurugan +4 more
- Vol. 7, Iss: 4, pp 23-23
TLDR
This literature review reviews the research on using current chemotherapy drugs and natural compounds and the beneficial effects they have on various types of cancers including non-small cell lung cancer and proposes the use of these compounds along with chemotherapy drugs in patients with advanced and/or refractory solid tumours.Abstract:
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum. Recent advances have enabled biologists to better investigate the potential use of natural compounds for the treatment or control of various cancerous diseases. For the past 30 years, natural compounds have been the pillar of chemotherapy. However, only a few compounds have been tested in cancerous patients and only partial evidence is available regarding their clinical effectiveness. Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. Based on this literature review, we propose the use of these compounds along with chemotherapy drugs in patients with advanced and/or refractory solid tumours.read more
Citations
More filters
Journal ArticleDOI
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer
Parvarish Sharma,Meenu Mehta,Daljeet Singh Dhanjal,Simran Kaur,Gaurav Gupta,Harjeet Singh,Lakshmi Thangavelu,Shanmugam Rajeshkumar,Murtaza M. Tambuwala,Hamid A. Bakshi,Dinesh Kumar Chellappan,Kamal Dua,Saurabh Satija +12 more
TL;DR: In this review, various modes of nano drug delivery options like liposomes, dendrimers, quantum dots, carbon nanotubes and metallic nanoparticles have been discussed.
Journal ArticleDOI
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
Alessandro Leonetti,Birgit Wever,Giulia Mazzaschi,Yehuda G. Assaraf,Christian Rolfo,Federico Quaini,Marcello Tiseo,Elisa Giovannetti,Elisa Giovannetti +8 more
TL;DR: A detailed overview of the immunobiological rationale and molecular basis for combining immune checkpoint inhibitors with chemotherapy for the treatment of advanced NSCLC and current evidence and future perspectives towards a better selection of patients who are more likely to benefit from chemo-immunotherapy combinations are discussed.
Journal ArticleDOI
Myricetin: A review of the most recent research.
Xiaominting Song,Lu Tan,Miao Wang,Chaoxiang Ren,Chuanjie Guo,Bo Yang,Yali Ren,Zhixing Cao,Yuzhi Li,Jin Pei +9 more
TL;DR: Theoretical basis for the clinical application of MYR is provided and a reference for its further use, and the potential molecular mechanisms of its effects are discussed.
Journal ArticleDOI
Friend or Foe: S100 Proteins in Cancer.
Chantal Allgöwer,Anna-Laura Kretz,Silvia von Karstedt,Mathias Wittau,Doris Henne-Bruns,Johannes Lemke +5 more
TL;DR: A review article summarises S100 proteins and their relation in different cancer types, while also providing an overview of novel therapeutic strategies for targeting S 100 proteins for cancer treatment.
Journal ArticleDOI
Old wine in new bottles: Drug repurposing in oncology
TL;DR: A number of promising candidates, such as aspirin, artesunate, cimetidine, doxycycline, ivermectin, metformin, rapamycin, and thalidomide, that have the potential to be repurposed as anticancer drugs both in cancer prevention and therapy are provided.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Cancer statistics, 2007.
TL;DR: While the absolute number of cancer deaths decreased for the second consecutive year in the United States, much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years.
Journal ArticleDOI
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Related Papers (5)
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra,Gitishree Das,Leonardo Fernandes Fraceto,Leonardo Fernandes Fraceto,Estefania Vangelie Ramos Campos,Estefania Vangelie Ramos Campos,Maria del Pilar Rodriguez-Torres,Laura Susana Acosta-Torres,Luis A. Diaz-Torres,Renato Grillo,Mallappa Kumara Swamy,Shivesh Sharma,Solomon Habtemariam,Han-Seung Shin +13 more